查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971794

慢性腎臟病市場分析及預測（至2035年）：按類型、產品類型、服務、技術、組件、應用、最終用戶、設備、功能和解決方案分類

Chronic Kidney Disease Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Device, Functionality, Solutions
出版日期: | 出版商: Global Insight Services | 英文 359 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

慢性腎臟病（CKD）市場預計將從2024年的529億美元成長到2034年的1,028億美元，複合年成長率約為6.9%。 CKD市場涵蓋腎功能衰退的診斷、治療和管理，包括藥物、透析設備和移植服務。由於慢性腎臟病老化和文明病， CKD盛行率不斷上升，推動了對創新治療方法和早期檢測工具的需求。對個人化醫療和經濟高效護理模式的重視正在塑造市場動態，而診斷和治療技術的進步則提供了巨大的成長機會。

由於治療方法的進步和疾病盛行率的上升，慢性腎臟病市場預計將迎來強勁成長。其中，促紅血球生成素促效劑細分市場佔據主導地位，該細分市場可有效治療與腎臟病相關的貧血。腎素-血管收縮素-醛固酮系統抑制劑緊隨其後，由於其在延緩疾病進展方面的作用，需求量不斷成長。透析領域也展現出巨大的潛力，其中血液透析表現最佳，反映了其廣泛的應用和顯著的療效。腹膜透析位居第二，因其便利性和居家治療選擇而日益普及。穿戴式和攜帶式透析設備等創新技術有望徹底改變患者護理，從而提高患者的生活品質和治療依從性。診斷領域，特別是生物標記發現和檢驗細分市場，正在快速發展，為早期檢測和個人化治療策略提供了可能。這種充滿活力的市場環境為相關人員投資新型治療方法和技術提供了絕佳的機會。

市場區隔
按類型 糖尿病腎臟病、高血壓腎臟病、腎絲球腎炎、多囊性腎病變、慢性腎臟病－礦物質和骨骼疾病
產品 藥品、透析機、腎臟移植相關產品、診斷設備、營養補充品
服務 透析服務、居家醫療保健服務、遠距醫療服務、營養諮詢、病患教育服務
科技 透析技術、生物標記技術、基因體學、蛋白質體學、奈米技術
成分 軟體、硬體、耗材和試劑
應用 診斷、治療、監測和監視
最終用戶 醫院、腎臟護理中心、居家醫療機構、研究機構、大學附設醫院
裝置 血液透析機、腹膜透析機、穿戴式人工腎臟、連續性腎臟替代療法裝置
功能 自動化系統、手動系統、智慧型系統
解決方案 綜合護理解決方案、慢性病管理和病人參與解決方案

市場概況：

慢性腎臟病(CKD) 市場正經歷著市場佔有率的動態變化，這主要得益於創新產品的推出和策略性定價模式的最佳化。製藥公司正致力於開發新型療法以滿足未被滿足的醫療需求，並擴大市場佔有率。定價策略也在不斷最佳化，以確保藥物的可及性並維持盈利。此外，生技公司與醫療服務提供者之間的合作也迅速增加，以加速最先進治療的應用。 CKD 市場的競爭異常激烈，主要企業在研發方面投入大量資金以獲得競爭優勢。法規結構，尤其是在北美和歐洲，透過嚴格的指導方針影響產品核可和市場准入，對塑造市場動態至關重要。對競爭對手的比較分析凸顯了對個人化醫療和生物製藥日益成長的關注。在患病率不斷上升、診斷技術不斷進步以及一系列前景廣闊的治療方法的推動下，該市場正呈現出成長的跡象。

主要趨勢和促進因素：

慢性腎臟病(CKD) 市場正經歷著變革性成長，這主要得益於幾個關鍵趨勢和促進因素。人口老化以及糖尿病和高血壓發病率的上升導致 CKD 盛行率不斷攀升，是推動市場成長的關鍵因素。這些疾病是 CKD 的主要風險因素，因此亟需加強檢測和治療方案。診斷工具和治療調查方法的技術進步正在顯著影響市場。基於生物標記的診斷和穿戴式健康監測設備等創新技術，使得早期檢測和個人化治療方案成為可能。人工智慧 (AI) 在醫療保健領域的應用，進一步完善了診斷和治療方案。政府主導和醫療保健政策正在推動早期篩檢和提高公眾意識，從而促進市場成長。健保報銷政策也日趨優惠，讓病患更容易獲得先進的治療方案。此外，對居家透析和遠端醫療服務的日益重視，擴大了患者獲得醫療保健服務的管道，為市場擴張提供了廣泛的機會。

限制與挑戰：

慢性腎臟病（CKD）市場面臨許多重大限制和挑戰。其中一個關鍵限制因素是治療高成本，限制了患者的就醫途徑，尤其是在低收入地區。這種經濟障礙往往導致診斷和治療延誤，加劇疾病進展。此外，腎臟科醫師和專科醫護人員長期短缺，導致病患管理和照護不足。這種短缺影響了及時介入和製定全面治療方案。同時，CKD市場也面臨患者對早期症狀和預防措施認知不足的問題，導致患者確診時往往已處於晚期。監管環境也是一大挑戰，新治療方法的嚴格核准流程減緩了市場准入和創新。最後，缺乏標準化的治療通訊協定也阻礙了市場發展，導致護理和治療結果不一致。這些挑戰疊加在一起，阻礙了CKD市場有效解決方案的成長和開發。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 糖尿病腎臟病
    • 高血壓腎臟病
    • 腎絲球腎炎
    • 多囊腎
    • 慢性腎臟病－礦物質和骨骼代謝紊亂
  • 市場規模及預測：依產品分類
    • 製藥
    • 透析機
    • 腎臟移植產品
    • 診斷設備
    • 營養補充品
  • 市場規模及預測：依服務分類
    • 透析服務
    • 家庭醫療保健服務
    • 遠端醫療服務
    • 營養諮詢
    • 病人教育服務
  • 市場規模及預測：依技術分類
    • 透析技術
    • 生物標記技術
    • 基因組學
    • 蛋白質體學
    • 奈米科技
  • 市場規模及預測：依組件分類
    • 軟體
    • 硬體
    • 消耗品
    • 試劑
  • 市場規模及預測：依應用領域分類
    • 診斷
    • 治療
    • 監測
    • 調查
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 腎臟護理中心
    • 居家醫療環境
    • 研究所
    • 學術醫療中心
  • 市場規模及預測：依設備分類
    • 血液透析機
    • 腹膜透析機
    • 穿戴式人工腎臟
    • 連續性腎臟替代治療裝置
  • 市場規模及預測：依功能分類
    • 自動化
    • 手動的
    • 智慧系統
  • 市場規模及預測：按解決方案分類
    • 綜合護理解決方案
    • 慢性病照護管理
    • 病人參與方案

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Akebia Therapeutics
  • Reata Pharmaceuticals
  • ChemoCentryx
  • Otsuka Pharmaceutical
  • Keryx Biopharmaceuticals
  • Vifor Pharma
  • Calliditas Therapeutics
  • Relypsa
  • Tricida
  • FibroGen
  • AstraZeneca
  • Cara Therapeutics
  • Rockwell Medical
  • Angion Biomedica
  • Chinook Therapeutics

第9章：關於我們

簡介目錄
Product Code: GIS33710

Chronic Kidney Disease Market is anticipated to expand from $52.9 billion in 2024 to $102.8 billion by 2034, growing at a CAGR of approximately 6.9%. The Chronic Kidney Disease (CKD) Market encompasses the diagnosis, treatment, and management of kidney function deterioration. It includes pharmaceuticals, dialysis equipment, and transplant services. Rising CKD prevalence, driven by aging populations and lifestyle diseases, is fueling demand for innovative therapies and early detection tools. Emphasis on personalized medicine and cost-effective care models is shaping market dynamics, with technological advancements in diagnostics and treatment offering significant growth opportunities.

The Chronic Kidney Disease Market is poised for robust growth, propelled by advancements in treatment modalities and increasing prevalence of the disease. The pharmaceuticals segment dominates, with the erythropoietin-stimulating agents sub-segment leading due to their efficacy in managing anemia associated with kidney disease. Renin-angiotensin-aldosterone system inhibitors follow, driven by their role in slowing disease progression. The dialysis segment also shows significant promise, with hemodialysis emerging as the top-performing sub-segment, reflecting its widespread use and effectiveness. Peritoneal dialysis is the second-highest performer, gaining traction for its convenience and home-based treatment options. Innovative technologies, such as wearable and portable dialysis devices, are set to revolutionize patient care, enhancing quality of life and compliance. The diagnostics segment, particularly the biomarker discovery and validation sub-segment, is rapidly advancing, offering potential for early detection and personalized treatment strategies. This dynamic landscape presents lucrative opportunities for stakeholders to invest in novel therapies and technologies.

Market Segmentation
TypeDiabetic Kidney Disease, Hypertensive Kidney Disease, Glomerulonephritis, Polycystic Kidney Disease, Chronic Kidney Disease-Mineral and Bone Disorder
ProductPharmaceuticals, Dialysis Equipment, Kidney Transplantation Products, Diagnostic Instruments, Nutritional Supplements
ServicesDialysis Services, Home Healthcare Services, Telemedicine Services, Nutritional Counseling, Patient Education Services
TechnologyDialysis Technology, Biomarker Technology, Genomics, Proteomics, Nanotechnology
ComponentSoftware, Hardware, Consumables, Reagents
ApplicationDiagnosis, Treatment, Monitoring, Research
End UserHospitals, Renal Care Centers, Homecare Settings, Research Institutes, Academic Medical Centers
DeviceHemodialysis Machines, Peritoneal Dialysis Machines, Wearable Artificial Kidneys, Continuous Renal Replacement Therapy Devices
FunctionalityAutomated, Manual, Smart Systems
SolutionsIntegrated Care Solutions, Chronic Care Management, Patient Engagement Solutions

Market Snapshot:

The Chronic Kidney Disease (CKD) market is witnessing a dynamic shift in market share, driven by innovative product launches and strategic pricing models. Pharmaceutical companies are focusing on developing novel therapeutics that address unmet patient needs, thereby enhancing their market presence. Pricing strategies are being optimized to ensure accessibility while maintaining profitability. The market is also characterized by a surge in collaborations between biotech firms and healthcare providers, aiming to expedite the introduction of cutting-edge treatments. Competition in the CKD market is intense, with leading companies investing heavily in R&D to gain a competitive edge. Regulatory frameworks, particularly in North America and Europe, are pivotal in shaping market dynamics, with stringent guidelines influencing product approvals and market entry. Benchmarking against competitors reveals a focus on personalized medicine and biologics. The market is poised for growth, driven by increasing prevalence rates, advancements in diagnostic technologies, and a robust pipeline of potential therapies.

Geographical Overview:

The Chronic Kidney Disease (CKD) market exhibits diverse growth trends across various regions, each presenting unique opportunities. North America remains a dominant force, driven by advanced healthcare infrastructure and heightened awareness of CKD management. The region's proactive approach to early diagnosis and treatment bolsters market growth. Europe follows closely, with robust healthcare policies and increasing prevalence of lifestyle-related diseases contributing to market expansion. The Asia Pacific region is witnessing rapid growth, fueled by rising healthcare expenditure and a growing patient pool. Emerging economies such as India and China are at the forefront, driven by improving healthcare access and increasing CKD awareness. Latin America is also experiencing growth, supported by government initiatives and healthcare reforms. Meanwhile, the Middle East & Africa region holds potential, with increasing investments in healthcare infrastructure aiming to address the rising CKD burden. These regions present lucrative opportunities for stakeholders to capitalize on emerging market dynamics.

Key Trends and Drivers:

The Chronic Kidney Disease (CKD) market is experiencing transformative growth driven by several key trends and drivers. The rising prevalence of CKD, fueled by an aging population and increasing incidence of diabetes and hypertension, is a primary driver. These conditions are major risk factors for CKD, necessitating enhanced detection and treatment options. Technological advancements in diagnostic tools and treatment methodologies are significantly impacting the market. Innovations such as biomarker-based diagnostics and wearable health monitoring devices are enabling earlier detection and personalized treatment approaches. The integration of artificial intelligence in healthcare is further refining diagnosis and treatment plans. Government initiatives and healthcare policies are promoting early screening and awareness programs, propelling market growth. Reimbursement policies are also becoming more favorable, easing access to advanced treatments. Additionally, the growing emphasis on home-based dialysis and telemedicine services is expanding patient access to care, offering lucrative opportunities for market expansion.

Restraints and Challenges:

The Chronic Kidney Disease (CKD) market encounters several significant restraints and challenges. A primary constraint is the high cost of treatment options, which limits accessibility for patients, particularly in low-income regions. This financial barrier often results in delayed diagnosis and treatment, exacerbating disease progression. Moreover, there is a persistent shortage of nephrologists and specialized healthcare providers, leading to inadequate patient management and care. This scarcity affects timely interventions and comprehensive treatment plans. Additionally, the CKD market struggles with low patient awareness about early symptoms and preventive measures, causing late-stage diagnoses. The regulatory landscape presents another challenge, with stringent approval processes for new therapies, delaying market entry and innovation. Finally, the market is hindered by the lack of standardized treatment protocols, which causes variability in care and outcomes. These challenges collectively impede the growth and development of effective solutions in the CKD market.

Key Players:

Akebia Therapeutics, Reata Pharmaceuticals, ChemoCentryx, Otsuka Pharmaceutical, Keryx Biopharmaceuticals, Vifor Pharma, Calliditas Therapeutics, Relypsa, Tricida, FibroGen, AstraZeneca, Cara Therapeutics, Rockwell Medical, Angion Biomedica, Chinook Therapeutics

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Device
  • 2.9 Key Market Highlights by Functionality
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Diabetic Kidney Disease
    • 4.1.2 Hypertensive Kidney Disease
    • 4.1.3 Glomerulonephritis
    • 4.1.4 Polycystic Kidney Disease
    • 4.1.5 Chronic Kidney Disease-Mineral and Bone Disorder
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Pharmaceuticals
    • 4.2.2 Dialysis Equipment
    • 4.2.3 Kidney Transplantation Products
    • 4.2.4 Diagnostic Instruments
    • 4.2.5 Nutritional Supplements
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Dialysis Services
    • 4.3.2 Home Healthcare Services
    • 4.3.3 Telemedicine Services
    • 4.3.4 Nutritional Counseling
    • 4.3.5 Patient Education Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Dialysis Technology
    • 4.4.2 Biomarker Technology
    • 4.4.3 Genomics
    • 4.4.4 Proteomics
    • 4.4.5 Nanotechnology
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Software
    • 4.5.2 Hardware
    • 4.5.3 Consumables
    • 4.5.4 Reagents
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Diagnosis
    • 4.6.2 Treatment
    • 4.6.3 Monitoring
    • 4.6.4 Research
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Renal Care Centers
    • 4.7.3 Homecare Settings
    • 4.7.4 Research Institutes
    • 4.7.5 Academic Medical Centers
  • 4.8 Market Size & Forecast by Device (2020-2035)
    • 4.8.1 Hemodialysis Machines
    • 4.8.2 Peritoneal Dialysis Machines
    • 4.8.3 Wearable Artificial Kidneys
    • 4.8.4 Continuous Renal Replacement Therapy Devices
  • 4.9 Market Size & Forecast by Functionality (2020-2035)
    • 4.9.1 Automated
    • 4.9.2 Manual
    • 4.9.3 Smart Systems
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Integrated Care Solutions
    • 4.10.2 Chronic Care Management
    • 4.10.3 Patient Engagement Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Device
      • 5.2.1.9 Functionality
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Device
      • 5.2.2.9 Functionality
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Device
      • 5.2.3.9 Functionality
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Device
      • 5.3.1.9 Functionality
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Device
      • 5.3.2.9 Functionality
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Device
      • 5.3.3.9 Functionality
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Device
      • 5.4.1.9 Functionality
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Device
      • 5.4.2.9 Functionality
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Device
      • 5.4.3.9 Functionality
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Device
      • 5.4.4.9 Functionality
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Device
      • 5.4.5.9 Functionality
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Device
      • 5.4.6.9 Functionality
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Device
      • 5.4.7.9 Functionality
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Device
      • 5.5.1.9 Functionality
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Device
      • 5.5.2.9 Functionality
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Device
      • 5.5.3.9 Functionality
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Device
      • 5.5.4.9 Functionality
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Device
      • 5.5.5.9 Functionality
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Device
      • 5.5.6.9 Functionality
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Device
      • 5.6.1.9 Functionality
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Device
      • 5.6.2.9 Functionality
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Device
      • 5.6.3.9 Functionality
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Device
      • 5.6.4.9 Functionality
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Device
      • 5.6.5.9 Functionality
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Akebia Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Reata Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 ChemoCentryx
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Otsuka Pharmaceutical
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Keryx Biopharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Vifor Pharma
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Calliditas Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Relypsa
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Tricida
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 FibroGen
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 AstraZeneca
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Cara Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Rockwell Medical
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Angion Biomedica
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Chinook Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us